Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial

1. Climent, M.Á.
2. Pérez-Valderrama, B.
3. Mellado, B.
4. Fernández Parra, E.M.
5. Fernández Calvo, O.
6. Ochoa de Olza, M.
7. Muinelo Romay, L.
8. Anido, U.
9. Domenech, M.
10. Hernando Polo, S.
11. Arranz Arija, J.Á.
12. Caballero, C.
13. Juan Fita, M.J.
14. Castellano, D.